Clinical Trial

Effect of Xuebijing InjecTion on Outcomes in Sepsis Patients Under Real-World Conditions（EXIT-SEP REAL）

Name: Effect of Xuebijing InjecTion on Outcomes in Sepsis Patients Under Real-World Conditions（EXIT-SEP REAL） — clinical trial record (NCT07069894)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: EXIT-SEP REAL

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

Xuebijing injection (XBJ) showed proven efficacy in the EXIT-SEP trial (NCT03238742), lowering 28-day mortality. However, its real-world effectiveness requires validation due to the trial's strict criteria. Broader clinical evaluation is imperative.

Trial Details

NCT Number	NCT07069894
Lead Sponsor	Southeast University, China
Conditions	Sepsis
Enrollment	5,400 participants
Start Date	2025-08-01
Primary Completion	2026-10 (estimated)
Study Completion	2027-09 (estimated)
Updated on ClinicalTrials.gov	2025-07-17